Welcome to our dedicated page for Biomx news (Ticker: PHGE), a resource for investors and traders seeking the latest updates and insights on Biomx stock.
BiomX Inc. (PHGE) news is centered on the company’s transition from a legacy phage therapy profile toward defense, security, critical infrastructure, and first-response technologies. Recent company announcements focus heavily on Zorronet, an AI defense technology subsidiary that develops command-and-control, computer vision, and autonomous surveillance systems.
PHGE news can include acquisition updates, material agreements, customer deployments, and operating details tied to Zorronet and DFSL. Zorronet-related coverage has included AI command-and-control software, secure on-premise and hybrid C5ISR deployments, mobile field-operator tools, and the use of cameras, sensors, drones, and IoT devices in integrated security environments.
Infrastructure and government-related items are also important for BiomX coverage. Company disclosures have discussed Zorronet’s work with Israel Railways, contracts with the Israel Defense Forces, and engagements involving government customers, Tier-1 OEMs such as Elbit Systems, and international clients. DFSL adds another news angle through LADAR-based detection systems for perimeter security, critical infrastructure, and counter-UAS markets.
BiomX news may also include SEC filing events, shareholder votes, governance changes, capital-structure disclosures, and operating results. Because the company has disclosed substantial doubt about its ability to continue as a going concern, financing and liquidity-related disclosures are also material to PHGE coverage. For investors tracking PHGE, the main news themes are defense technology acquisitions, operational deployments, critical infrastructure agreements, and the company’s remaining phage therapy background.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BiomX (PHGE) announced positive results from Part 1 of its Phase 1b/2a trial for BX004 targeting lung infections in cystic fibrosis (CF) patients. The treatment showed a significant bacterial load reduction of over 90% compared to placebo and no safety concerns. Enrollment for Part 2 is ongoing, with results expected in Q3 2023. Financially, BiomX reported a cash balance of $34.3 million as of Dec 31, 2022, down from $63.1 million the previous year. The company estimates its cash runway extends through mid-2024, supported by a $7.5 million private placement and a $5 million award from the Cystic Fibrosis Foundation.
BiomX Inc. (NYSE American: PHGE) has announced a conference call and live audio webcast on March 29, 2023, at 8:00 a.m. ET to discuss its fourth quarter and full year 2022 financial results along with business updates. The event will provide insights into the company's progress in developing natural and engineered phage therapies targeting pathogenic bacteria. Interested participants can join by dialing 1-877-407-0724 (U.S.) or 1-201-389-0898 (International), with the live and archived webcast available on BiomX's website.